VAGUSX Trademark

Trademark Overview


On Thursday, October 12, 2023, a trademark application was filed for VAGUSX with the United States Patent and Trademark Office. The USPTO has given the VAGUSX trademark a serial number of 98221719. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 17, 2024. This trademark is owned by InflammaSense, Inc. The VAGUSX trademark is filed in the Medical Instrument Products category with the following description:

Medical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals; Medical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals with integrated recorded operating system software, sold as a unit; Medical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals with integrated recorded software using artificial intelligence, machine learning, and deep learning to decode nervous system language response signals to detect sepsis and inflammatory disease, sold as a unit
vagusx

General Information


Serial Number98221719
Word MarkVAGUSX
Filing DateThursday, October 12, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, September 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 23, 2024

Trademark Statements


Goods and ServicesMedical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals; Medical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals with integrated recorded operating system software, sold as a unit; Medical devices for use in treating or diagnosing sepsis and inflammatory disease using a non-invasive patch to record and measure biological signs, cytokine signals and neural signals with integrated recorded software using artificial intelligence, machine learning, and deep learning to decode nervous system language response signals to detect sepsis and inflammatory disease, sold as a unit

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, October 12, 2023
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameInflammaSense, Inc
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNEW YORK, NY 10001

Party NameInflammaSense, Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNEW YORK, NY 10001

Trademark Events


Event DateEvent Description
Thursday, October 12, 2023NEW APPLICATION ENTERED
Sunday, December 31, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 30, 2024ASSIGNED TO EXAMINER
Thursday, June 6, 2024NON-FINAL ACTION E-MAILED
Thursday, June 6, 2024NON-FINAL ACTION WRITTEN
Thursday, June 6, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 10, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 10, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 18, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 17, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 10, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED